Welcome to our dedicated page for Royalty Pharma news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma stock.
Royalty Pharma plc reports developments tied to its biopharmaceutical royalty portfolio and life-sciences funding model. The company acquires existing royalties from medicine innovators and enters direct funding arrangements, including co-funding for late-stage clinical trials and product launches, in exchange for future royalties.
Recurring news covers Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, royalty transactions, and updates from commercial products and development-stage candidates. Company announcements also address R&D funding collaborations, portfolio clinical and regulatory developments, leadership additions in partnering and technology, investor conference appearances, and scientific initiatives such as the Royalty Pharma Translational Prize.
Royalty Pharma (Nasdaq: RPRX) has successfully priced an offering of $1.3 billion in senior unsecured notes. This includes $600 million of 2.15% Senior Notes due in 2031 and $700 million of 3.35% Senior Notes due in 2051. The proceeds from the Social Bonds will support investments aligned with United Nations Sustainable Development Goals, while the 2051 Notes will finance general corporate purposes. The offering is set to close on July 26, 2021, pending customary conditions.
Royalty Pharma plc (Nasdaq: RPRX) announced its participation in two investor conferences in June 2021. The first event is the Goldman Sachs Global Healthcare Conference on June 9 at 3:50 p.m. EDT, followed by the Bank of America Napa Biopharma Conference on June 15 at 1:30 p.m. EDT. Interested parties can access webcasts from Royalty Pharma’s “Events” page, with recordings available for at least 30 days. Royalty Pharma is the largest buyer of biopharmaceutical royalties, funding innovation in the industry and holding royalties on over 45 commercial products.
Royalty Pharma has announced a $2.025 billion strategic funding partnership with MorphoSys to facilitate its $1.7 billion acquisition of Constellation Pharmaceuticals. This agreement includes an upfront payment of $1.425 billion, milestone payments of up to $150 million, and up to $350 million in Development Funding Bonds. Royalty Pharma will acquire future royalties from the blockbuster drug Tremfya, with 2020 sales reaching $1.347 billion, and rights to royalties from four development-stage therapies. The deal aims to enhance Royalty Pharma's portfolio and supports MorphoSys’s growth strategy.
Royalty Pharma (RPRX) reported strong Q1 2021 results, with GAAP net cash from operations rising 12% to $526 million and total revenues up 14% to $573 million. Adjusted Cash Receipts surged 37% to $524 million, driven by growth in its cystic fibrosis and oncology portfolios. The company announced new royalty transactions totaling $787 million, including $582 million in upfront payments. Royalty Pharma raised its 2021 Adjusted Cash Receipts guidance to $1,940-$1,980 million, reflecting positive business momentum and portfolio expansion.
Royalty Pharma plc (Nasdaq: RPRX) will participate in three investor conferences in May 2021: the Bank of America 2021 Healthcare Conference on May 12, the Truist Securities Life Sciences Summit on May 20, and the UBS Global Healthcare Virtual Conference on May 24. All events will be accessible via the company’s Events page, and webcasts will be archived for at least thirty days.
Royalty Pharma is a leading buyer of biopharmaceutical royalties, funding innovation in the industry and holding royalties on over 45 commercial products.
Royalty Pharma (Nasdaq: RPRX) will report its first quarter 2021 financial results on May 11, 2021, before U.S. markets open. A conference call is scheduled for the same day at 8:00 a.m. ET, accessible via phone or live webcast on the company’s website. Royalty Pharma, established in 1996, is the largest buyer of biopharmaceutical royalties, collaborating with a variety of innovators and funding late-stage clinical trials. The company owns royalties from over 45 commercial products, contributing to its strong industry presence.
Royalty Pharma (Nasdaq: RPRX) announced a collaboration with MSCI Inc. to create new thematic indexes focused on innovation in the life sciences, specifically targeting virology and oncology. This partnership will leverage Royalty Pharma's expertise in medical conditions and clinical trials to assist MSCI in developing index methodologies. The new indexes aim to capture performance metrics of companies delivering advanced therapeutic treatments. The launch is expected later this year, showcasing Royalty Pharma's commitment to monetizing its intellectual capital in life sciences.
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved a dividend payment of $0.17 per class A share for the second quarter of 2021. This dividend will be paid on June 15, 2021, to shareholders on record as of May 20, 2021. Royalty Pharma is recognized as the largest purchaser of biopharmaceutical royalties and plays a significant role in funding innovation in the biopharmaceutical sector, partnering with a range of companies to enhance their product launches and clinical trials.
Royalty Pharma has acquired Dicerna's royalty interest in OXLUMO for $180 million upfront and up to $60 million in sales-based milestones. OXLUMO, approved for treating primary hyperoxaluria type 1, is marketed by Alnylam Pharmaceuticals. This deal will extend Dicerna's cash runway into 2024, enhancing its ability to fund clinical operations, including the development of its lead candidate, nedosiran. Both companies highlight the innovative nature of RNAi therapeutics as a significant focus of this transaction.
Dicerna Pharmaceuticals (Nasdaq: DRNA) has agreed to sell its royalty interest in OXLUMO™ to Royalty Pharma (Nasdaq: RPRX) for an upfront payment of $180 million, plus potential sales-based milestones of up to $60 million. OXLUMO is FDA and EMA approved for treating primary hyperoxaluria type 1 and marketed by Alnylam Pharmaceuticals. This transaction is expected to extend Dicerna's cash runway into 2024, supporting ongoing clinical plans. The deal reflects Dicerna's commitment to addressing unmet medical needs in rare diseases, specifically primary hyperoxaluria.